NCT02633813 - BE Study of Naftifine HCL | Biotech Hunter

Enrollment

693

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

December 31, 2015

Conditions

Tinea Pedis

Interventions

DRUG

Naftifine hydrochloride 2%

Topical application for two weeks

DRUG

Placebo

Topical application for two weeks

DRUG

Naftin® 2% (Naftifine hydrochloride 2%)

Topical application for two weeks

Trial Locations (14)

10305

Instituto Dermatológico, Barrio Maria Auxiliadora

33014

Savin Medical Group Research, Miami

33027

FXM Research Miramar, Miramar

33144

International Dermatology Research, Inc,, Miami

33175

FXM Research Corp, Miami

33511

Moore Clinical Research Inc, Brandon

33609

South Tampa, MOORE Clinical Research, Inc., Tampa

33618

North Tampa MOORE Clinical Research, Inc., Tampa

64506

Medi Search, Saint Joseph

75093

Research Across America, Plano

75149

Family Practise, Mesquite

75234

Research Across America, Dallas

77401

Bellaire Dermatology Associates, Bellaire

91000

Instituto Dermatológico y Cirugía de Piel, Santo Domingo